Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Impact of QRS duration on survival benefit with prophylactic implantable cardioverter-defibrillators: a meta-analysis of randomized controlled trials.

Sipahi I, Chaudhry SP, Issa M, Ambati M, Dagdelen S, Fang JC.

J Cardiovasc Med (Hagerstown). 2015 Dec;16(12):811-6. doi: 10.2459/JCM.0b013e3283657524. Review.

PMID:
25010502
2.

Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials.

Katritsis DG, Siontis KC, Bigger JT, Kadish AH, Steinman R, Zareba W, Siontis GC, Bardy GH, Ioannidis JP.

Heart Rhythm. 2013 Feb;10(2):200-6. doi: 10.1016/j.hrthm.2012.10.039. Epub 2012 Oct 27. Review.

PMID:
23107652
3.

Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.

Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C.

Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255.

PMID:
19752408
4.

Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials.

Ezekowitz JA, Armstrong PW, McAlister FA.

Ann Intern Med. 2003 Mar 18;138(6):445-52. Review.

PMID:
12639076
5.

Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.

Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O'Conner C, Levy WC.

J Am Coll Cardiol. 2017 May 30;69(21):2606-2618. doi: 10.1016/j.jacc.2017.03.568.

PMID:
28545633
6.

Cardiac-resynchronization therapy in patients with systolic heart failure and QRS interval ≤130 ms: insights from a meta-analysis.

Shah RM, Patel D, Molnar J, Ellenbogen KA, Koneru JN.

Europace. 2015 Feb;17(2):267-73. doi: 10.1093/europace/euu214. Epub 2014 Aug 27. Review.

PMID:
25164431
7.

New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.

Friedman DJ, Al-Khatib SM, Zeitler EP, Han J, Bardy GH, Poole JE, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LYT, Sanders GD.

Am Heart J. 2017 Sep;191:21-29. doi: 10.1016/j.ahj.2017.06.002. Epub 2017 Jun 9. Review.

PMID:
28888266
8.
9.

Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators.

Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P, Pelargonio G, Natale A.

Ann Intern Med. 2010 Nov 2;153(9):592-9. doi: 10.7326/0003-4819-153-9-201011020-00009. Review. Erratum in: Ann Intern Med. 2011 Jun 7;154(11):780.

PMID:
21041579
10.

The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis.

Stavrakis S, Lazzara R, Thadani U.

J Cardiovasc Electrophysiol. 2012 Feb;23(2):163-8. doi: 10.1111/j.1540-8167.2011.02144.x. Epub 2011 Aug 4.

PMID:
21815961
11.

Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies.

Makki N, Swaminathan PD, Hanmer J, Olshansky B.

Europace. 2014 Jan;16(1):55-62. doi: 10.1093/europace/eut277. Epub 2013 Sep 20. Review.

PMID:
24058182
12.
13.
14.
15.

Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review.

Earley A, Persson R, Garlitski AC, Balk EM, Uhlig K.

Ann Intern Med. 2014 Jan 21;160(2):111-21. Review.

PMID:
24592496
16.

The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.

Henyan NN, White CM, Gillespie EL, Smith K, Coleman CI, Kluger J.

J Intern Med. 2006 Nov;260(5):467-73.

17.

Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.

Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV.

Circ Arrhythm Electrophysiol. 2014 Feb;7(1):164-70. doi: 10.1161/CIRCEP.113.001217. Epub 2014 Jan 20. Review.

18.

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.

Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2008 Jun 11;299(22):2656-66. doi: 10.1001/jama.299.22.2656.

PMID:
18544725
19.

Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.

Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, Sanders GD.

JACC Heart Fail. 2014 Dec;2(6):623-9. doi: 10.1016/j.jchf.2014.06.007. Epub 2014 Oct 8.

20.

Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction.

Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, McAlister FA.

Ann Intern Med. 2007 Aug 21;147(4):251-62. Review.

PMID:
17709759

Supplemental Content

Support Center